Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.00 (0.00%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £2.72m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Director Dealing

12 Dec 2017 10:17

RNS Number : 0902Z
Physiomics PLC
12 December 2017
 

12th December 2017

Physiomics plc

("Physiomics") or ("the Company")

 

Director Dealing

 

The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:

 

Director

Number of shares sold

Sale price per share

Dr J Millen, CEO

240,000

8.3p

Dr C Chassagnole, COO

600,000

8.3p

 

Following the sales of shares, the total holdings of each Director of the Company will be as follows:

 

Dr Paul Harper 525,707

Dr Jim Millen 444,641

Dr Christophe Chassagnole 417,008

 

The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

240,000

d)

Aggregated information

- Aggregated volume

- Price

 

240,000

At 8.3p per share

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Disposal of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

8.3p

600,000

d)

Aggregated information

- Aggregated volume

- Price

 

600,000

At 8.3p

e)

Date of the transaction

12-12-2017

f)

Place of the transaction

XLON, AIM

 

 

 

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHTTBMTMBBBBIR
Date   Source Headline
29th Jan 20102:20 pmRNSTotal Voting Rights
29th Jan 20102:17 pmRNSHolding(s) in Company
22nd Jan 20101:14 pmRNSIssue of Equity
29th Dec 200910:53 amRNSResult of AGM
18th Dec 20091:06 pmRNSConversion of Loan Note
14th Dec 200912:46 pmRNSIssue of Equity
9th Dec 20097:47 amRNSHolding(s) in Company
4th Dec 200911:47 amRNSIssue of Equity
25th Nov 20099:16 amRNSHolding(s) in Company
19th Nov 20099:03 amRNSHolding(s) in Company
16th Nov 20094:50 pmRNSHolding(s) in Company
16th Nov 20097:00 amRNSPhysiomics Presentation
6th Nov 20094:30 pmRNSHolding(s) in Company
5th Nov 20094:22 pmRNSHolding(s) in Company
27th Oct 20094:18 pmRNSHolding(s) in Company
27th Oct 20099:35 amRNSHolding(s) in Company
23rd Oct 20094:23 pmRNSHolding(s) in Company
21st Oct 20099:06 amRNSHolding(s) in Company
20th Oct 20094:01 pmRNSHolding(s) in Company
20th Oct 20093:59 pmRNSHolding(s) in Company
16th Oct 20094:30 pmRNSRecent Price Movements
1st Oct 20093:02 pmRNSTrading Statement
18th Sep 200910:02 amRNSHolding(s) in Company
11th Sep 20093:52 pmRNSHolding(s) in Company
8th Sep 200912:37 pmRNSHolding(s) in Company - Replacement
7th Sep 20094:35 pmRNSHolding(s) in Company
3rd Sep 20099:12 amRNSHolding(s) in Company
28th Aug 20097:56 amRNSTotal Voting Rights
17th Aug 200910:01 amRNSHolding(s) in Company
6th Aug 20094:23 pmRNSConversion of Debt into Equity
24th Jul 20098:01 amRNSHolding(s) in Company
6th Jul 200911:52 amRNSHolding(s) in Company
2nd Jul 20097:53 amRNSHolding(s) in Company
26th Jun 20097:58 amRNSHolding(s) in Company
23rd Jun 20097:00 amRNSUpdate on EC funded TEMPO project
23rd Apr 20094:34 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
20th Apr 20097:00 amRNSSeminar Presentation
2nd Apr 20097:00 amRNSLicense Agreement with Eli Lilly
1st Apr 20097:00 amRNSChange of Adviser
20th Mar 200912:33 pmRNSHolding(s) in Company
5th Mar 20093:20 pmRNSHolding(s) in Company
10th Feb 20097:30 amRNSHalf Yearly Report
26th Jan 200911:30 amRNSHolding(s) in Company
5th Jan 200910:45 amRNSHolding(s) in Company
19th Dec 200810:58 amRNSResult of AGM
19th Dec 200810:46 amRNSHolding(s) in Company
12th Dec 20087:30 amRNSPlacing of Shares
27th Nov 20087:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.